Clinical Trial Update: Evaluating the Safety of Extended Treatment With Pegsunercept (PEG sTNF-RI)in Subjects With Rheumatoid Arthritis (RA) [Phase 2]

View source ↗

Summary

Phase 2 trial evaluating safety of extended Pegsunercept therapy in rheumatoid arthritis has completed.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Rheumatoid Arthritis

Drugs mentioned

• Pegsunercept (pegylated soluble TNF receptor I)

Snippet

Sponsor: Amgen | Conditions: Rheumatoid Arthritis | Phase 2 | Status: COMPLETED